Bio-Rad Labs (NYSE: BIO) reported Q2 EPS of $2.61, $0.88 better than the analyst estimate of $1.73. Revenue for the quarter came in at $651.6 million versus the consensus estimate of $615.2 million.

Updated Full-Year 2025 Financial Outlook

Bio-Rad is updating its financial outlook for the full year 2025. The company currently expects non-GAAP, currency-neutral revenue growth of approximately 0 to 1.0 percent versus its prior estimated range of approximately a 1.0 percent decline to 1.5 percent growth. Non-GAAP operating margin is now estimated to be approximately 12.0 to 13.0 percent compared to the company’s prior expectation of approximately 10.0 to 12.0 percent.

For earnings history and earnings-related data on Bio-Rad Labs (BIO) click here.